XML 79 R15.htm IDEA: XBRL DOCUMENT v2.4.1.9
Goodwill and In-Process Research and Development
12 Months Ended
Mar. 31, 2015
Goodwill and In-Process Research and Development

Note 8. Goodwill and In-Process Research and Development

The carrying amount of goodwill at March 31, 2015 and 2014 was $31.5 million and $38.0 million, respectively, and has been recorded in connection with the Company’s acquisition of Impella Cardiosystems AG, or Impella, in 2005 and ECP and AIS in July 2014. The goodwill activity is as follows:

 

     March 31, 2015  
     (in $000’s)  

Balance at March 31, 2013

   $ 35,410   

Foreign currency translation impact

     2,580   
  

 

 

 

Balance at March 31, 2014

   $ 37,990   

Additions

     1,964   

Foreign currency translation impact

     (8,420
  

 

 

 

Balance at March 31, 2015

   $ 31,534   
  

 

 

 

 

The Company has no accumulated impairment losses on goodwill. The Company performed a Step 0 qualitative assessment during the annual impairment review for fiscal 2015 as of October 31, 2014 and concluded that it is not more likely than not that the fair value of the Company’s single reporting unit is less than its carrying amount. Therefore, the two-step goodwill impairment test for the reporting unit was not necessary in fiscal 2015.

As described in Note 3. “Acquisitions,” in July 2014, the Company acquired ECP and AIS and recorded $18.5 million of IPR&D. The estimated fair value of the IPR&D was determined using a probability-weighted income approach, which discounts expected future cash flows to present value. The projected cash flows from the expandable catheter pump technology were based on certain key assumptions, including estimates of future revenue and expenses, taking into account the stage of development of the technology at the acquisition date and the time and resources needed to complete development. The Company used a discount rate of 22.5% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.

The carrying value of the Company’s IPR&D assets and the change in the balance for the year ended March 31, 2015 is as follows:

 

     March 31,
2015
 
     (in $000’s)  

Beginning balance

   $ —     

Additions

     18,500   

Foreign currency translation impact

     (3,789
  

 

 

 

Ending balance

   $ 14,711